Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Rivaroxaban (Xarelto, BAY59-7939
Rivaroxaban Xarelto, BAY59-7939 · 1 trial · 1 indication
Only PK will be tested in central lab
Only PK will be tested in central lab
| Arm | Type | Description |
|---|---|---|
| Rivaroxaban | EXPERIMENTAL | Single arm, open label study |
| Name | Type | Description |
|---|---|---|
| Rivaroxaban (Xarelto, BAY59-7939 | DRUG | Single dose of reconstituted rivaroxaban granules |
Inclusion Criteria: * Children with an age ≥2 months and weight between 3 and \<12 kg, who have completed anticoagulant treatment at least 10 days prior to the planned study drug administration. * Gestational age at birth of at least 37 weeks * Oral feeding/ nasogastric/ gastric feeding for at...
Top 2 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | REGN | 3 | PHASE3 | REGN7508 |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE2 | Thrombate III |
Rivaroxaban is used for the treatment of thrombosis, a condition involving blood clots. It is a small molecule drug developed by Bayer AG under the ticker BAYRY. The clinical program includes a Phase 1 study in children with thrombosis, evaluating an oral suspension granule formulation.
Rivaroxaban targets coagulation factor Xa, also known as F10. It acts as an inhibitor of this enzyme, which plays a central role in the blood coagulation cascade. By inhibiting factor Xa, rivaroxaban reduces thrombin generation and clot formation.
Rivaroxaban is developed by Bayer AG, which trades under the ticker BAYRY. Bayer AG is the company responsible for the clinical development of the drug, including the Phase 1 trial in pediatric patients with thrombosis.
Rivaroxaban is in Phase 1 clinical development for thrombosis. The only listed trial is a completed Phase 1 study. It is an investigational drug and has not been approved by the FDA for this indication based on the available information.
Rivaroxaban has been studied in a Phase 1 trial, NCT02497716, titled 'Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children.' The trial enrolled 47 participants with thrombosis across the United States, Belgium, Canada, Finland, France, Hungary, Italy, and Spain, and is completed.
Yes, Rivaroxaban is also known as Xarelto and BAY59-7939. These are alternative names for the same drug substance. Rivaroxaban is the international nonproprietary name, Xarelto is a brand name, and BAY59-7939 is a development code used by Bayer AG.